Table 2.
The concentration of catecholamines in plasma after 3,4-DAP.
| Groups | WKY | SHR | ||
|---|---|---|---|---|
| Norepinephrine (nM) | Epinehrine (nM) | Norepinephrine (nM) | Epinephrine (nM) | |
| Time controls (PBS+PBS)a | 0.5±0.0 | 7.9±1.6 | 1.2±0.2† | 10.8±2.7 |
| PBS+3,4-DAP | 1.1±0.2 | 8.5±1.4 | 5.5±0.6* | 18.5±5.2 |
| Hexamethonium+3,4-DAPb | 2.5±0.3† | 3.4±1.0† | ||
| Reserpine+PBS+3,4-DAP | 1.1±0.6† | 11.1±2.6 | ||
| Methoctramine+PBS+3,4-DAP | 1.1±0.1 | 7.7±3.2 | 13.1±2.8† | 26.9±11.8 |
| XE-991+3,4-DAP | 3.3±0.7† | 11.6±4.2 | 35.6±9.1† | 125.5±27.4† |
| Hexamethonium+XE-991+3,4-DAP | 11.5±3.6‡⊢ | 35.9±12.6‡⊢ | ||
| Reserpine+XE-991+3,4-DAP | 4.4±0.9‡⊢ | 17.2±4.0‡ | ||
| Methoctramine+XE-991+3,4-DAP | 35.7±7.3†⊢ | 88.1±28.7† | ||
| Chromanol+3,4-DAP | 6.8±2.1 | 35.0±23.5 | ||
| Retigabine+3,4-DAP | 0.8±0.2 | 3.9±1.4 | 4.7±0.5 | 12.3±2.2 |
| Reserpine+retigabine+3,4-DAP | 1.0±0.3†‡ | 9.7±2.1‡ | ||
| ICA-27243+3,4-DAP | 6.5±2.3 | 18.5±11.5 | ||
| Reserpine+ICA-27243+3,4-DAP | 1.4±1.0† | 5.8±2.0 | ||
Arterial blood was collected at the end of the experiment. Significant differences between the WKY and SHR 3,4-DAP controls (*), between the 3,4-DAP-control and experimental groups within each strain (†), and in SHR between corresponding groups pre-treated with channel drug and reserpine/ hexamethonium/methoctramine+channel drug (‡), and between corresponding groups pre-treated reserpine/hexamethonium/methoctramine and reserpine/ hexamethonium/methoctramine+channel drug (⊢) were detected as indicated.
a
most rats in this groups was from Berg and Jensen (2011).
b
from Berg (2015).
*,†,‡,⊢
P < 0.05.